Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

NCT04998786

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHR Annecy, France
  • CH de la cote basque Bayonne, France
  • CHRU Hopital Haut Lévêque Bordeaux, France
  • CHU Caen, France
View all 21 locations
View Trial Details
Active, Not Recruiting

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
  • The First Hospital of Jilin University Changchun, China
  • West China Hospital, Sichuan University Chengdu, China
View all 16 locations
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Fort Myers, Florida, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Kansas City, Missouri, United States
View all 122 locations
View Trial Details
Active, Not Recruiting

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Nagoya, Aichi-ken, Japan
  • GSK Investigational Site Kamogawa, Chiba, Japan
  • GSK Investigational Site Kashiwa, Chiba, Japan
  • GSK Investigational Site Matsuyama, Ehime, Japan
View all 13 locations
View Trial Details

Related conditions